BRAF and cancer: These include larotrectinib, entrectinib, and repotrectinib for NTRK-mutated cancers; pembrolizumab for high microsatellite instability (MSI-high), mismatch repair gene-deficient (dMMR), or high-tumor-mutation-burden (TMB) cancers; dabrafenib and trametinib for cancers with BRAF V600E mutation; selpercatinib for cancers with RET gene fusions; and fam-trastuzumab deruxtecan for cancers with an overexpression of HER2 oncoprotein.